Table 1 Baseline patient characteristics.
Variables | Total (N = 547) | N2a (N = 242) | N2b (N = 129) | p value |
---|---|---|---|---|
Age | 63.1 ± 9.5 | 62.7 ± 8.8 | 61.0 ± 11.6 | 0.132 |
≤ 50 year | 62 (11.3%) | 23 (9.5%) | 30 (23.3%) | 0.001 |
> 50 year | 485 (88.7%) | 219 (90.5%) | 99 (76.7%) | |
Sex | ||||
F | 113 (20.7%) | 51 (21.1%) | 37 (28.7%) | 0.13 |
M | 434 (79.3%) | 191 (78.9%) | 92 (71.3%) | |
The number of Comorbidity | ||||
0 | 261 (47.7%) | 122 (50.4%) | 67 (51.9%) | 0.452 |
1 | 174 (31.8%) | 68 (28.1%) | 41 (31.8%) | |
2 | 112 (20.5%) | 52 (21.5%) | 21 (16.3%) | |
FEV1 | 84.7 ± 15.7 | 85.8 ± 16.0 | 86.7 ± 14.5 | 0.626 |
DLCO | 81.8 ± 17.1 | 82.3 ± 17.5 | 83.7 ± 14.7 | 0.412 |
Smoking | ||||
No | 111 (20.9%) | 40 (17.8%) | 42 (32.6%) | 0.002 |
Yes | 419 (79.1%) | 185 (82.2%) | 87 (67.4%) | |
Histology | ||||
Adenocarcinoma | 242 (44.2%) | 109 (45.0%) | 94 (72.9%) | < 0.001 |
SqCC | 261 (47.7%) | 112 (46.3%) | 26 (20.2%) | |
Others | 44 (8.0%) | 21 (8.7%) | 9 (7.0%) | |
N2 LN biopsy | ||||
Yes | 159 (29.1%) | 73 (30.2%) | 53 (41.1%) | 0.045 |
No | 388 (70.9%) | 169 (69.8%) | 76 (58.9%) | |
Mediastinal LN evaluation | ||||
EBUS | 128 (23.4%) | 57 (23.6%) | 41 (31.8%) | 0.113 |
EUS | 2 (0.4%) | 0 (0%) | 1 ( 0.8%) | |
Mediastinoscope | 29 (5.3%) | 16 (6.6%) | 11 ( 8.5%) | |
None | 388 (70.9%) | 169 (69.8%) | 76 (58.9%) | |
PreOP confirmed N2 | ||||
Yes | 125 (22.9%) | 68 (28.1%) | 53 (41.1%) | 0.015 |
No | 422(77.1%) | 174 (71.9%) | 76 (58.9%) | |
Cancer size (PreOP) | 42.4 ± 20.9 | 39.9 ± 17.8 | 40.4 ± 21.2 | 0.831 |
Clinical T staging | ||||
T1 | 122 (22.3%) | 63 (26.0%) | 31 (24%) | 0.017 |
T2 | 239 (43.7%) | 96 (39.7%) | 42 (32.6%) | |
T3 | 123 (22.5%) | 55 (22.7%) | 48 (37.2%) | |
T4 | 63 (11.5%) | 28 (11.6%) | 8 (6.2%) | |
Clinical staging | ||||
IIIA | 361 (66.0%) | 159 (65.7%) | 73 (56.6%) | 0.106 |
IIIB | 186 (34.0%) | 83 (34.3%) | 56 (43.4%) | |
OP type | 0.366 | |||
Open | 397 (72.6%) | 174 (71.9%) | 89 (69.0%) | |
VATS | 150 (27.4%) | 68 (28.1%) | 40 (31.0%) | |
OP extent | 1 | |||
Segmentectomy | 4 (0.7%) | 2 (0.8%) | 1 (0.8%) | |
Lobectomy | 405 (74.0%) | 183 (75.6% | 103 (79.8%) | |
Bilobectomy | 65 (11.9%) | 26 (10.7%) | 14 (10.9%) | |
Pneumonectomy | 45 (8.2%) | 19 (7.9%) | 8 (6.2%) | |
Sleeve lobectomy | 28 (5.1%) | 12 (5.0%) | 3 (2.3%) | |
Resection margin | 1 | |||
R0 | 478 (87.4%) | 207 (85.5%) | 115 (89.1%) | |
R1 | 61 (11.2%) | 29 (12.0%) | 12 (9.3%) | |
R2 | 8 (1.5%) | 6 (2.5%) | 2 (1.6%) | |
Cancer size (PostOP) | 44.6 ± 21.8 | 43.0 ± 20.7 | 42.2 ± 21.1 | 0.016 |
Pathologic T staging | 1 | |||
T1 | 93 (17.0%) | 37 (15.3%) | 25 (19.4%) | |
T2 | 243 (44.4%) | 118 (48.8%) | 61 (47.3%) | |
T3 | 130 (23.8%) | 52 (21.5%) | 30 (23.3%) | |
T4 | 81 (14.8%) | 35 (14.5%) | 13 (10.1%) | |
Pathologic M staging | 1 | |||
M0 | 541 (98.9%) | 237 (97.9%) | 129 (100%) | |
M1a | 6 (1.1%) | 5 (2.1%) | 0 (0.0%) |